Health Policy

Fuatilia
SPD politicians criticizing Health Minister Nina Warken's unbalanced health savings package in Bundestag debate, demanding pharma cuts.
Àwòrán tí AI ṣe

SPD criticizes imbalance in Warken's health savings package

Ti AI ṣe iroyin Àwòrán tí AI ṣe

Days before the planned cabinet decision, the SPD warns against overburdening insured individuals with Health Minister Nina Warken's savings package. The SPD demands more cuts from pharmaceutical companies and efficiency measures. The Greens have presented their own counter-concept.

The Korean government's plan to extend National Health Insurance coverage to hair-loss medication is facing growing criticism from patient groups and medical experts.

Ti AI ṣe iroyin

Federal Health Minister Nina Warken has called on the states to lower building standards for care homes. The goal is to reduce nursing care costs.

In an RND interview, Federal Medical Association President Klaus Reinhardt discusses Germany's high doctor visit rates, which he does not attribute solely to patient behavior. He warns against planned prescribing rights for pharmacists and advocates for a sugar tax as well as smartphone bans in schools. Additionally, he supports a new regulation of assisted suicide with strict protective measures.

Ti AI ṣe iroyin Ti ṣayẹwo fun ododo

Actress Cheryl Hines said in a recent interview with Dr. Phil McGraw that her husband, Health and Human Services Secretary Robert F. Kennedy Jr., at one point suggested the couple publicly claim they were separated to reduce the political backlash she was facing. Hines said she did not consider doing so.

In the second Trump administration, Heritage Foundation scholars are pressing Health and Human Services Secretary Robert F. Kennedy Jr. to order "gold standard" studies and expand informed-consent requirements for oral contraceptives, arguing the pills carry underappreciated health and ecological costs.

Ti AI ṣe iroyin

A U.S. federal judge has ruled that the Food and Drug Administration (FDA) possesses the authority to regulate lab-developed tests (LDTs) as medical devices. This decision comes amid ongoing debates over the oversight of in-house diagnostic tools used by clinical laboratories.

 

 

 

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ